Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx to Develop Biochips Using Dyax s Phage Display Technology

NEW YORK, March 27 - In an effort to develop its protein biochips, Zyomyx said Tuesday it has licensed phage display antibody technology from Dyax.

The agreement is the second antibody collaboration for Zyomyx, which first teamed up with Cambridge Antibody Technology (CAT) last December for access to antibodies in CAT's phage display libraries. 

In the arrangement with Dyax, Zyomyx will receive a non-exclusive license to Dyax's phage display technology for developing antibodies to specific proteins for use in a protein biochip. The companies did not disclose financial terms of the deal, but said that the agreement involves both fees for R&D and royalties on future product sales.

Last week, diagnostics manufacturer Biosite said it had developed a prototype protein microarray with 100 antibodies. While Zyomyx has yet to announce the development of a large-scale prototype, Zyomyx CEO Lawrence Cohen said recently that the company plans to release beta versions of chips that will have densities of up to 10,000 proteins per square centimeter later this year.

Zyomyx, of Hayward, Calif., also has partnerships with Fujirebo, a Japanese developer of diagnostics tools, and MDS Proteomics of Toronto.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.